The Role of the “Cancer Stem Cell Niche” in Cancer Initiation and Progression by Noll, Jacqueline E. et al.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors




the world’s leading publisher of
Open Access books






The Role of the “Cancer Stem Cell Niche”
in Cancer Initiation
and Progression
Jacqueline E. Noll, Kate Vandyke and
Andrew C.W. Zannettino
Additional information is available at the end of the chapter
http://dx.doi.org/10.5772/58598
1. Introduction
1.1. Cancer stem cells: An introduction
Adult stem cells, also known as progenitor cells, have two major ascribed functions: (1) to
replenish tissues throughout normal growth and development and (2) to repair tissues
following damage by disease or injury. Classically, a stem cell is defined as possessing the
capacity for self-renewal and potency. Self-renewal requires a stem cell to be able to divide in
such a way as to maintain the pool of stem cells in an undifferentiated state, while potency
(commonly referred to as pluri- or multi-potency) requires a stem cell to retain the capacity to
differentiate into an array of specialized cell types. Cancer stem cells (CSC) represent a subset
of tumour cells that exhibit the same properties as normal adult stem cells; namely the ability
to self-renew, undergo asymmetric cell division and differentiate into a diverse range of cell
types. In addition, the CSC population has the capacity to initiate tumours and has also been
implicated in metastatic spread and in resistance to conventional anti-cancer therapies.
The majority of cells within a tumour are unable to sustain tumour growth and cannot initiate
tumour establishment at secondary locations. The small population of cells that are inherently
tumourigenic and commonly have a metastatic phenotype are referred to as CSC. CSC were
initially identified and characterised in acute myeloid leukaemia (AML) [1]. In this study, a
minority of the total tumour cell population (0.01-1%) was identified as having the unique
capacity to induce leukemia following transplantation into immunodeficient mice implying
that these cells alone had a tumour-initiating capacity. Following from this study, the ability
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of cells to cause tumour development in immune-compromised animals has been used both
as proof-of-principle for the existence of CSC and a means of identifying CSC or tumour-
initiating cells. Since the initial discovery of CSC, our knowledge and understanding of this
area has increased exponentially, with CSC identified in an array of solid tumours beginning
with breast cancer [2] and glioma [3, 4] and subsequently extending to prostate [5], pancreatic
[6], melanoma [7], liver [8] and head and neck [9] cancers, among others.
As discussed throughout this chapter, the reliance of the CSC on their specific niche is a current
area of research focus. Importantly, as our understanding of the signalling pathways and
specific interactions that modulate and maintain CSC function (and subsequently tumour
initiation and development) increases, we will become better placed to formulate novel
treatment modalities that will not only target the tumour cells for destruction but also focus
on abolishing integral factors within the supportive CSC niche. Novel treatments such as these
will aim to eradicate residual CSC, resulting in a decrease in tumour recurrence following
therapy and better overall prognosis for cancer patients.
2. CSC markers
The isolation of CSC from total tumour cell populations has been made possible due to the
identification of CSC-specific markers. The use of these markers to classify and identify
tumour-initiating cells and circulating tumour cells has allowed the investigation of the
importance of CSC in the developing tumour, particularly in metastasis, drug resistance and
patient prognosis. However, due to the similarities in cell surface phenotype and marker
expression between CSC and normal adult stem cells, further research is needed to aid in our
ability to distinguish between malignant stem cells and those required for normal tissue
regeneration processes. Ideally, in the future, CSC-specific markers will be used to therapeut‐
ically target CSC for eradication. Notably, in-roads have already been made in this area.
CD44 has been identified as a CSC marker and its expression has been associated with high
levels of metastasis, tumour recurrence and poor outcome in breast cancer, all factors associ‐
ated with CSC sub-populations within tumours. Although it has been well characterised,
there is some controversy regarding the specificity of CD44 to CSC as the full-length CD44
protein is widely expressed. However, recent studies have identified CSC-specific expres‐
sion of a particular splice variant of CD44 [10, 11]. Aldehyde dehydrogenase isoform 1
(ALDH1) is another commonly used marker of CSC from a range of cancer types [12, 13],
however similarly to CD44, ALDH1 expression is also associated with normal haemato‐
poietic stem cells and therefore can be used as a marker of both normal and malignant stem
cells [14]. A range of other markers have also been identified, with some CSC markers, in‐
cluding CD133, CD44 and ALDH1, remaining consistent across a number of tumour types.
These are summarised in Table 1.
Adult Stem Cell Niches292
Tumour Type CSC Phenotypic Markers Selected References
Breast CD44+ CD21-/low Lineage- ALDH1+ CD133+ α6-integrin [2, 13, 15, 16]
AML CD34+ CD38- [1]
Liver CD133+ CD49f+ CD90+ CD44+ [8, 17, 18]
Lung CD133+ CD90+ ALDH1+ [19-21]
Glioma CD133+ Nestin+ CD90+ α6-integrin [3, 4, 22-24]
Colon CD133+ CD44+ CD24+ [25, 26]
Prostate CD133+CD44+ α2β1high ALDH1+ [5, 27]
Pancreatic CD44+ CD24+ CD133+ ALDH1+ EpCAM+ Nestin
+ABCG2high
[6, 28-30]
Melanoma CD20+ CD166+ CD133+ Nestin+ CD271+ [7, 31, 32]
Head and Neck CD44+ CD133+ ALDH+ [9, 33]
Table 1. Representative cell surface phenotypic markers for human CSCs.
3. CSC niche components and function
The function and maintenance of stem cells is highly reliant on the specific anatomical and
physiological location in which these cells reside. This highly specialised microenvironment
in which stem cells are located is commonly referred to as the stem cell niche. The niche is
made up of stromal support cells, soluble factors, blood vessels and extracellular matrix pro‐
teins that have both direct and indirect effects on stem cell number, proliferation, self-re‐
newal and fate determination. The niche is essential for the maintaining the balance between
pro- and anti-proliferative signals to ensure a controlled stem cell environment. In fact, stem
cells outside of their defined niche are reported to have limited function as they are highly
reliant on cell-cell interactions and signals within their local microenvironment for their ba‐
sic proliferative and tissue renewal properties [34]. Importantly, in the context of CSC, the
niche plays an important role in maintenance of stem cell function, tumour initiation and
protection against chemotherapeutic agents. The reliance of CSC on the niche is becoming
increasingly evident as studies have shown that while CSC-like cells can be isolated from
cancer cell lines in vitro, these cell populations are difficult to maintain in an in vitro setting
[35, 36]. In contrast, xenograft models have proven to be effective in faithfully recapitulating
the characteristics of the CSC as found in the original tumour [37]. This is likely due to the
ability of the CSC to grow within a supportive tumour microenvironment, or niche, and as
such respond to cellular interactions and local signalling pathways.
The CSC niche may be derived through one of two mechanisms; either the CSC specifically
manufacture the niche through the production of numerous factors that signal between stro‐
mal cells of the local microenvironment and the CSC themselves or, conversely, the CSC uti‐
lise the pre-existing, tissue-specific stem cell niche. The latter option results in the CSC
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“hijacking” the niche that would normally modulate the normal growth and development of
local stem cells. It is clear that in both normal stem cell and CSC development and mainte‐
nance, there is a mutual dependence between the stem cells and their niche.
As discussed in detail throughout this chapter, both the CSC themselves and the stromal
cells of the CSC niche secrete a variety of factors and signalling molecules to modulate path‐
ways that are normally involved in growth and development. Together, these factors func‐
tion to maintain CSC, support the maintenance of the CSC niche and promote tumour
development. In addition, physiological consequences of tumour formation, such as the es‐
tablishment of a hypoxic microenvironment and the subsequent induction of angiogenesis
and neovascularisation, can result in a positive feed-forward effect on CSC. Furthermore,
not only do CSC rely on factors expressed within the niche to ensure the maintenance of the
CSC population, but the CSC themselves can regulate the composition and function of the
niche [38, 39]. In this manner, the CSC and the niche function together to create a positive
signalling loop to maintain a state conducive to the growth and further development of tu‐
mours.
4. CSC and metastasis
The metastatic potential of tumour cells relies not only on genetic alterations and expression
of factors from the tumour cell itself, but also on interactions with structural, soluble and
cellular components of the extracellular matrix (ECM) and stromal tissue compartment.
These signals from the stromal microenvironment are required for the formation of what is
termed the “pre-metastatic niche” and similarly to the CSC niche at the site of primary tu‐
mour establishment, this niche is a highly specialised microenvironment that aids in the mi‐
gration, homing and colonisation of tumour cells, as well as subsequently enhancing tumour
cell proliferation and disease development.
4.1. Epithelial-mesenchymal transition
Epithelial-mesenchymal transition (EMT) was originally described as an important process
in early embryonic development, and has also been described as a significant feature in a
number of cancers. Molecular markers of EMT include an increase in the expression of N-
cadherin and vimentin coupled with decreased expression of E-cadherin, increased accumu‐
lation of β-catenin within the nucleus, increased secretion of matrix metalloproteinases
(MMPs) and increased expression and activity of a number of transcription factors including
SLUG, SNAIL and TWIST. Cells that have undergone an EMT exhibit a loss of epithelial cell
polarity and intracellular adhesion accompanied by reorganisation of the cytoskeleton,
which together results in an increased capacity for migration, invasion and cell scattering
(reviewed in [40]). EMT in tumourigenesis has been described in detail in recent years with
a large number of studies supporting a role for EMT in tumour progression, particularly the
process of metastasis. In addition, the EMT process has been closely associated with the for‐
mation, and subsequent behaviour, of CSC populations. A number of different stimuli regu‐
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late and drive EMT both in development and disease. These include: signalling through
specific pathways (e.g. TGFβ, Wnt, Notch and Hedgehog), direct cellular interactions and
exposure to hypoxic conditions – all factors that also play key roles in the maintenance of
CSC (as discussed throughout this chapter).
The process of EMT and the maintenance of CSC are closely linked, with the induction of
EMT enriching for a CSC-like population. This has been observed by multiple means, in‐
cluding the observation that metastatic cells exhibit both an EMT- and CSC-like phenotype.
Experimental evidence has demonstrated that circulating tumour cells in both prostate and
breast cancers express both CSC and mesenchymal markers [41, 42]. In addition, induction
of EMT in human mammary epithelial cells results not only in the acquisition of mesenchy‐
mal markers, but also the expression of a CSC phenotype, for example CD44+/CD24-/low in
breast cancer stem cells. The opposite is also seen to be true, with CSC-like cells expressing
markers similar to those found on cells that have undergone an EMT, including decreased
expression of E-cadherin and increased expression of N-cadherin, vimentin and Twist [43].
Notably, within a non-CSC population, the activation of EMT can in fact revert cells back to
a CSC-like state, suggesting that this transition is a key player in modulating CSC function.
It is likely, therefore, that the CSC population does, in fact, make up a large proportion of
the tumour cells that have undergone EMT and as such can be found in the peripheral circu‐
lation and therefore play an integral role in the establishment of secondary/metastatic tu‐
mours. This has been demonstrated specifically in prostate cancer, with the vast majority of
circulating tumour cells (those likely to be responsible for colonisation of distant metastatic
sites) expressing both the stem cell marker CD133, as well as a range of mesenchymal-asso‐
ciated proteins [42].
4.2. Migration and invasion
Recent studies suggest that the CSC population within tumours, although comprising a very
small percentage of the total tumour, are critical for metastatic colonisation and have been
shown to initiate tumour growth at secondary sites [44, 45]. The ability of cells to migrate
and invade is closely linked with their intrinsic ability to metastasise and colonise secondary
tumour locations. The mechanisms utilised by CSC to modulate their invasive capacity are
similar to those employed by normal stem cells for homing and/or mobilisation. Within the
haematopoietic stem cell (HSC) niche, MMPs play a role in HSC mobilisation through the
proteolysis of ECM components [46]. In addition, stem cell migration within both the hae‐
matopoietic and neural systems displays a reliance on integrins [47, 48]. Specific roles for
MMPs and integrins in cancer cell metastasis have also been described [49, 50]. The
CXCL12/CXCR4 axis (described in detail below) is also a key player in both normal and can‐
cer stem cell migration and invasion [51, 52].
There have been a number of recent discoveries that support a direct link between CSC and
the development of metastasis in cancer, as common pathways (including EMT) have been
identified as integral for both regulation of CSC and driving metastasis [53]. Furthermore,
CSCs have been demonstrated to be directly involved in metastasis in xenograft models of
cancer [54, 55], due largely to the enhanced invasive capacity of CSC. This can be attributed,
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at least in part, to increased MMP secretion by CSC [56]. Furthermore, comparison of the ge‐
netic profiles of breast CSCs and normal breast epithelium has identified an “invasive” gene
signature associated with the CSC population, which has been demonstrated to correlate
with a metastatic phenotype in breast cancer patients [53, 57].
5. Extracellular matrix components of the CSC niche
The ECM has defined roles in cellular proliferation, differentiation and migration as well as
tumour angiogenesis and protection from chemotherapy [58, 59] and represents an impor‐
tant component of the CSC niche. Receptors expressed within the ECM allow stem cells to
anchor to specific locations within the niche and therefore maintain signalling and contact
with other cells residing within the niche [58]. Loss of ECM contact with resident stem cells,
through reducing and/or inhibiting the ECM glycoprotein components, results in a decrease
in stem cell number [60, 61]. In addition, the ECM is also able to influence the behaviour of
stromal cells within the niche, including endothelial cells, immune cells and fibroblasts [58].
Increased expression of specific ECM glycoproteins has been associated with various tu‐
mour types, including breast and pancreatic cancers [62-66], which in turn have been associ‐
ated with poor prognosis [67]. The composition of the ECM is therefore critical in
maintaining tissue and cellular homeostasis and in modulating the growth and proliferation
of stem cells. Importantly, abnormal ECM dynamics compromise the role of the ECM as a
physical barrier to tumour cell invasion, allowing for cellular migration and invasion. Mod‐
ulation of the ECM, most commonly through enzymes such as MMPs that degrade the pro‐
teins making up the ECM, enhances cellular migration and subsequent colonisation of the
pre-metastatic niche by CSC. High expression of Tenascin-C, a glycoprotein expressed with‐
in the ECM, has been linked to metastasis in a range of different cancer types [68-70]. Anoth‐
er component of the ECM, periostin (POSTN), is expressed by the stroma of primary
tumours. Infiltrating tumour cells (i.e. cells undergoing metastasis) induce POSTN expres‐
sion within the secondary target organ to initiate colonisation, a function that can be suc‐
cessfully inhibited by blocking POSTN [71]. The processes of cellular migration and
invasion, and hence metastasis, therefore require significant modification of the ECM.
6. Stromal cells within the CSC niche
The CSC niche is composed of a range of specific cell types including fibroblasts, endothelial
cells, mesenchymal stem cells (MSC) and immune cells. The “stemness” of CSC is in fact a
dynamic quality that can be mediated by extrinsic cues derived from the local microenviron‐
ment. Direct cell-cell interactions between the stromal cell compartment and CSC, as well as
signalling pathways mediated through the expression and secretion of a range of growth
factors and cytokines play a role in the maintenance of the CSC population within the niche
and in overall tumour growth.
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6.1. Fibroblasts
The major cellular component of the tumour microenvironment is the stromal fibroblasts,
commonly referred to as carcinoma-associated fibroblasts (CAFs). Factors that are secreted
by fibroblasts within the tumour environment are able to revert differentiated tumour cells
to a CSC-like phenotype, thereby maintaining the CSC population. CAFs have specifically
been shown to alter the function of CSC through the expression of elevated levels of chemo‐
kine C-X-C motif ligand 12 (CXCL12) and MMP-1. The expression of CXCL12 by stromal fi‐
broblasts within the tumour microenvironment adds to the supportive role of the niche,
playing a role in the promotion of EMT in primary tumours ([72]; discussed in detail below).
Coupled with the expression of MMPs, CAFs may directly stimulate the migration of CSC
and therefore play a role in driving metastasis.
Tumour cells located in close proximity to stromal fibroblasts also exhibit increased expres‐
sion of Wnt pathway regulated genes (as discussed below). The association between the tu‐
mour cells and their stromal environment is critical in modulating pathways and gene
expression, both from the stromal cells (to create a permissive environment for CSC) and by
the tumour cells (to further tumour development and CSC maintenance).
6.2. Immune cells
Tumour-associated macrophages (TAMs) represent the major immune component of stro‐
mal cells in tumour microenvironments. TAMs are identified as M2-type macrophages and
as such express a range of factors that regulate matrix components resulting in remodelling
of the ECM, activation of angiogenic pathways, suppression of adaptive immunity and en‐
hancement of tumour cell proliferation and survival. Together, these functions cooperate to
promote tumour development (Reviewed in [73]). TAMs are recruited to sites of tumour for‐
mation due to the expression of chemokines by the tumour cells. It has recently been sug‐
gested that the CSC population plays a significant role in the recruitment and modulation of
TAM within the CSC niche. TAM recruitment factors, including soluble colony-stimulating
factor 1 (sCSF-1), transforming growth factor beta (TGFβ) and macrophage inhibitory cyto‐
kine 1 (MIC-1), are specifically expressed by tumour-derived CSC [74]. In glioma, the pres‐
ence of TGFβ-expressing TAM at the invasive tumour front has been correlated with the
presence of glioma CSC and these CSC are shown to have a greater invasive potential in the
presence of the TAMs [75]. In addition, CSC are able to promote the expression of IL-6 by
TAMs [76], hence further enhancing the pro-growth signalling for CSC within the local envi‐
ronment. The specific depletion of TAMs in pancreatic cancers results in a concomitant de‐
crease in the number of CSC [77]. It is apparent that the immune cell component of the CSC
niche is important in the regulation of CSC number and activity in tumours.
6.3. Endothelial cells
The CSC population is commonly located in what has been termed a “perivascular” niche
[78-80], which can best be defined by its anatomical/physical location directly adjacent to the
endothelial cells comprising the blood vessels. Indeed a number of studies have shown that
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the removal of endothelial cells from the perivascular niche results in a reduction in CSC
number, suggesting an absolute reliance on the cellular composition of the niche for mainte‐
nance and survival of CSC. Vascular endothelial cells interact directly with CSC and secrete
a range of factors that influence both tumour growth and CSC maintenance. A number of
studies have identified a range of secretory molecules that are produced by endothelial cells
and subsequently support the growth, self-renewal and migratory capacity of CSC, includ‐
ing Bmi-1, Jagged-1, vascular endothelial growth factor (VEGF), interleukin 6 (IL-6), inter‐
leukin 8 (IL-8, also known as CXCL8) and epidermal growth factor (EGF) [78, 80-84].
6.4. Mesenchymal stem cells
Mesenchymal stem cells (MSC) are multi-potent stromal cells with the capacity to differenti‐
ate into osteoblasts, adipocytes and chondrocytes to make up bone, fat and cartilage tissues
respectively. MSC are most commonly found within the bone marrow compartment; al‐
though, they have also been shown to reside in other tissue types. MSC have been implicat‐
ed with a role in tumour progression. This has been described in haematological cancers,
with an increase in MSC within the bone marrow being associated with myeloma disease
[85]. In addition, a role for MSC in tumour development has been described in a number of
solid cancers, including breast [86, 87], colon [88], lung [89] and prostate [90]. MSC injected
into tumour-bearing mice exhibit preferential homing to the site of cancer formation and the
presence of MSC within the local tumour environment was shown to accelerate tumour
growth [86, 87]. The presence of MSC within the local tumour microenvironment was specif‐
ically shown to promote an increase in the CSC population, which is likely due to the ex‐
pression of pro-proliferative factors by MSC, including CXCL12, IL-8 and IL-6 [87, 91-93].
These studies suggest that signalling between resident CSC and the MSC located within the
niche results in enhanced proliferative and self-renewal signals.
7. Angiogenesis and hypoxia
Angiogenesis is a key player in the development of tumours and is defined by the prolifera‐
tion of blood vessels within and around areas of established tumour, and aids in the supply
of nutrients and oxygen to the malignant cells. In addition, as discussed above, vascular en‐
dothelial cells play an important role in maintaining the CSC niche. Exposure to hypoxic
conditions, as are present in many solid tumours, results in the stabilisation of hypoxia in‐
ducible transcription factors (HIFs), which in turn mediate angiogenic pathways and stimu‐
late neovascularisation within the tumour and at distant, metastatic sites. Angiogenesis is
further regulated by a number of growth factors including VEGF and EGF.
The CSC population within the tumour, which (as previously discussed) has the potential to
initiate metastatic growth at a distant site, will undergo an EMT in response to the hypoxic
conditions present in the tumour microenvironment [94]. HIF-1α has multiple roles within
the tumour microenvironment, functioning as a master regulator of angiogenesis in hypoxic
conditions, maintaining the CSC niche and directly modulating the CSC population. HIF-1α
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promotes EMT in a number of human cancers through the increased expression of EMT
drivers (e.g. SNAIL) and the concurrent reduction of epithelial markers (e.g. E-Cadherin)
[95]. As has already been discussed, the CSC population has distinct similarities to cells that
have undergone an EMT, and as such it is plausible that this hypoxia-mediated EMT may
also directly affect the CSC population. Indeed, the CSC population isolated from tumours
following continuous cycles of hypoxia and re-oxygenation exhibit both stem-like and EMT-
like phenotypes [94]. In addition, hypoxia is a critical physiological component of the CSC
niche which functions to increase CSC number and maintain their stem-like state allowing
for subsequent growth and metastasis [94, 96]. These effects are likely due to the aforemen‐
tioned stabilisation of HIF-1α, which has a direct effect on CSC, enhancing their self-renewal
capacity, promoting cellular proliferation and increasing the tumorigenic properties of these
cells [94, 96, 97]. Together, these studies outline an important role for the hypoxic microen‐
vironment in establishing and maintaining the CSC niche.
In addition to the hypoxic environment and subsequent angiogenic induction having a pro-
growth effect on CSC, CSC are also able to promote angiogenesis. This can occur via both
direct and indirect mechanisms. Firstly, CSC differentiate into cells of the vascular endothe‐
lium, thereby functioning to create their own niche [39, 98]. Secondly, CSC secrete factors
that promote angiogenic induction. The CSC component of tumours exhibit a much greater
expression of the pro-angiogenic factor VEGF compared to the non-CSC population and
transplantation of these cells results in the formation of highly vascularised tumours in vivo
[38, 39]. Furthermore, expression of VEGF by vascular endothelial cells acts directly on CSC
to promote proliferation and stemness [78, 99]. VEGF expression is also regulated by EMT
and as such provides a possible link between the VEGF-mediated angiogenesis and EMT-
induced cancer stemness that is commonly observed in relation to CSC [100].
8. WNT/Notch/Hedgehog pathways
The Hedgehog (Hh), Wnt and Notch signalling pathways are involved in normal develop‐
ment and have also been implicated in tumour biology. These pathways have specific roles
in CSC maintenance and differentiation, as discussed in detail below. The CSC niche modu‐
lates expression of these pathways, highlighting the importance of extrinsic effects of the mi‐
croenvironment on signalling pathways within the CSCs.
Increased activity of the Hh pathway is associated with normal adult stem cell development,
with down-regulation of the pathway components common following stem cell differentia‐
tion. Similarly, increased expression and activation of the Hh pathway is a common feature
of CSC and has been described as an essential signalling component in CSC self-renewal
and tumour-initiating properties [101-105]. These studies outline a role for the Hh signalling
pathway in increasing CSC number and regulating the expression of CSC-related genes.
Furthermore, a reliance on Hh signalling has been demonstrated for the recurrence and
metastasis of xenograft tumours, most likely through the induction of EMT [105].
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Activation of the Wnt signalling pathway is common throughout numerous developmental
processes and is usually associated with the promotion of cell growth. This occurs through
ligands binding to specific cell surface receptors, including Frizzled and Lrp5/6, which in
turn mediates the inhibition of GSK3β and the subsequent accumulation of β-catenin within
the nucleus. Therein, β-catenin functions as a transcription factor, modulating the expres‐
sion of a range of genes that promote cellular growth and proliferation, including MYC
[106], IL-8 [107] and Cyclin D [108, 109]. It therefore follows that abnormal or constitutive
activation of the Wnt pathway will result in continuous signalling which promotes cell pro‐
liferation. Consequently, the Wnt inhibitors DKK1 and sFRP play a key role in regulating
this pathway to ensure a balance in proliferative signals is maintained.
Wnt signalling is known to play a role in promoting normal adult stem cell activation and
expansion, a function which is kept in check by the presence of specific Wnt inhibitors [110,
111]. In addition, bone morphogenic proteins (BMPs), which in general function to inhibit
cell growth, work in concert with the Wnt signalling pathway to provide a balance between
anti-and pro-growth signals to regulate stem cell self-renewal. However, in the context of
cancer, this balance can be disrupted, through both loss of BMP signalling or aberrant acti‐
vation of Wnt signalling, leading to uncontrolled proliferation of CSC [112]. The increase in
Wnt signalling activity in tumour cells has been associated with cells in close proximity to
the stromal fibroblasts, suggesting that modulation of this pathway may be through extrin‐
sic factors and as such a niche-dependent function [113].
The Notch signalling pathway has also been associated with increased growth and tumouri‐
genicity of CSC. High levels of Notch are observed in CSC populations, which have been
demonstrated to lead to EMT and increased capacity to form tumours upon transplantation
into immune-compromised animals [114-116]. Silencing Notch pathway signalling in CSC
results in reduced growth, migration and invasion as well as enhanced apoptotic induction
[117]. Furthermore, inhibition of Notch signalling has been demonstrated to inhibit tumour
growth and, more specifically, reduce the number of CSC in a number of cancer types in‐
cluding colon and brain [115, 118, 119]. In addition, expression of hairy and enhancer of split
1 (Hes1), a target of the Notch signalling pathway, correlates with the expression of stem cell
markers in colon cancer and is associated with self-renewal and increased tumourigenicty
[120]. This recent study suggests that activation of the Notch signalling pathway and subse‐
quent expression of target genes is an important component of maintaining CSC function.
The CSC population exhibits reliance on expression and deregulation of these developmen‐
tal pathways that are modulated by stromal cells of the CSC niche. Together, these findings
substantiate a reliance of the CSC on specific components of the niche. Specifically, these
pathways provide novel opportunities for targeting the niche and signals emanating from it
in an attempt to reduce CSC number in vivo and hence reduce the incidence of tumour re‐
currence following treatment.
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9. The role of the CXCL12-CXCR4 axis in CSC
CXCL12 (also known as SDF-1) is a strong chemo-attractant initially identified with a role in
the attraction of lymphocytes during haematopoiesis. In addition, CXCL12 has been demon‐
strated to play a role in immune signalling and inflammation and hence is an important reg‐
ulator of key physiological processes in both development and disease. However in recent
years, knowledge of its role has greatly diversified, particularly in the area of stem cell regu‐
lation and homing. The cognate receptor for CXCL12, CXCR4, is highly expressed on cells of
the haematopoietic lineage, thereby promoting the localisation of HSC within their specific
niche [121, 122]. Importantly, CXCR4 is also expressed on a range of stem cells including en‐
dothelial, haematopoietic, neural and embryonic stem cells, enabling these cells to respond
to gradients of CXCL12, which are generated following tissue damage and irregular physio‐
logical events such as hypoxia [123]. This results in the efficient migration and homing of
CXCR4 positive stem cells to areas of high CXCL12 expression, making the CXCL12-CXCR4
axis critical for normal development and tissue regeneration and repair.
In the context of human cancers, CXCR4 is highly expressed in many tumour types [124]
and has been shown to not only regulate invasion of cancer cells to metastatic sites, but to be
a marker of the CSC population of multiple tumour types [125, 126]. The CXCL12-CXCR4
axis has been implicated in metastatic processes in a range of cancers, including breast, pros‐
tate, lung, colon, kidney, melanoma, brain, leukaemia and myeloma, with expression of
CXCL12 highest in tissues that are common sites of metastasis, such as liver, bone marrow
and lungs [127], suggesting that tumour cells hijack this mechanism of normal tissue regen‐
eration and stem cell localisation to aid the metastatic process. In all, it is clear that the
CXCL12-CXCR4 axis plays an integral role in the development of metastasis and the defini‐
tion of a pre-metastatic niche. Importantly, it is the CSC population within the tumour that
is likely to utilise this axis for the development of distant metastases.
10. Cytokines and CSC regulation
Cytokines are a group of small molecules that are secreted by a broad range of cells, includ‐
ing immune cells, endothelial cells and fibroblasts. In general, following release by cells, cy‐
tokines act through binding their specific receptors on target cells and modulating immune
responses as well as regulating cell growth and behaviour. A number of cytokines have
been implicated in CSC maintenance and therefore are important secreted factors present
within the CSC niche.
IL-6 is a pro-inflammatory cytokine which normally functions to stimulate the immune re‐
sponse following injury or infection. Importantly, IL-6 is expressed by a range of cells within
the CSC niche, including macrophages and stromal fibroblasts, as well as CSC themselves,
and has been demonstrated to directly regulate CSC behaviour. IL-6 signalling specifically
through the STAT3 pathway has been identified as a key mechanism for the modulation of
CSC. STAT3 is highly expressed in CSC derived from liver, bone, cervical and brain cancers
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[128]. Furthermore, inhibition of the STAT3 pathway, through use of a specific STAT3 inhib‐
itor, has been demonstrated to reduce the formation of glioblastoma CSC [129]. IL-6 signal‐
ling is a direct regulator of breast cancer CSC self-renewal, leading to subsequent increased
expression and secretion of IL-6 and a resultant feed-forward loop that functions to further
enhance CSC function [130]. In addition, glioblastoma CSC are reliant on increased expres‐
sion of IL-6 to mediate growth, invasion and anti-apoptotic functions [131, 132]. Conversely,
the loss of IL-6 in mouse models results in reduction in gastric tumour formation [133].
These mechanistic studies provide an explanation as to why patients with advanced or
metastatic cancers exhibit increased serum expression of IL-6, which in turn is correlated
with poor prognosis [134, 135].
IL-6 function within the CSC niche is not strictly limited to the direct maintenance of CSC
self-renewal and growth, rather IL-6 also has an indirect effect on CSC through modulation
of the stromal cell composition of the CSC niche itself. In breast cancer, the production of
IL-6 by CSC acts as an attractant for MSC, resulting in the migration of MSC directly to sites
of breast tumour growth [87]. This is particularly important as MSC have been described to
play a major supportive role for CSC within their local microenvironment, promoting both
tumour growth and angiogenic induction (as described above).
Aside from IL-6, a number of other interleukins play important roles in the regulation of
CSC. IL-17 is expressed by cells within the tumour microenvironment and promotes the self-
renewal of CSC in ovarian cancer [136]. High levels of IL-1 have been associated with ad‐
vanced metastatic disease [137, 138], suggesting that it may also play a role in modulating
CSC and the metastatic niche. Notably, increased IL-1 production by TAMs has been shown
to increase angiogenesis and tumour cell growth as well as enhance metastasis [139]. Simi‐
larly, increased levels of IL-8 in serum are also correlated with more aggressive cancer and
subsequently poor prognosis [140, 141]. This is likely due to the ability of IL-8 to modulate
CSC self-renewal, and hence tumour growth, as the IL-8 receptor (CXCR1) is found to be
highly expressed on CSC [142]. IL-8 in the tumour microenvironment is secreted by endo‐
thelial cells located within the perivascular niche, providing another mechanism through
which the vasculature can induce CSC growth. In addition, the expression of IL-8 can also
increase the expression of the CXCR1 receptor on CSC, making the CSC even more respon‐
sive to further IL-8 signalling [81].
11. Prognosis
The identification of CSC within the bulk tumour, as made possible through the use of phe‐
notypic markers (see Table 1) has been shown to correlate with patient prognosis and sur‐
vival. The expression of CD44, a common CSC marker, has been associated with high levels
of metastasis, increased incidence of tumour recurrence following treatment, and as a result,
poor patient outcome. This is likely due to the key role the CSC sub-population plays in the
growth and development of tumours, both at the primary site and for establishment within
the metastatic niche. An increase in the CSC isolated from breast cancer patients using the
Adult Stem Cell Niches302
CD44high/CD24-/low phenotype was shown to correlate with more aggressive forms of disease
and poor patient prognosis [143, 144]. A similar correlation was also noted in pancreatic can‐
cer, with patients exhibiting increased expression of CD44 presenting with a median surviv‐
al of only 10 months, compared to 43 months in patients with low levels of CD44 [145]. High
ALDH1 expression was also demonstrated to correlate with poor prognosis in breast cancer
[13], rectal adenocarcinoma [146] and colorectal cancer [147]. Furthermore, ALDH1 expres‐
sion has also been shown to be indicative of tumour recurrence following treatment [148].
However, there remains some controversy in this area as high stromal cell expression of
ALDH1 within the tumour microenvironment has been associated with improved patient
outcome in breast cancer [149, 150], suggesting that use of stem cell markers as prognostic
indicators must be approached with some caution. CD133 expression was correlated with
metastasis in colorectal cancer patients, despite having no significant effect on overall sur‐
vival in the same study [147]. However, high levels of CD133 have been demonstrated to
correlate with poor clinical outcome in other studies [151, 152]. Other less commonly descri‐
bed markers of CSC, such as Nestin, have also been demonstrated to correlate with tumour
size and lymph node metastasis in non-small cell lung carcinoma and poor patient progno‐
sis in adenocarcinoma [153]. The analysis of CSC within a patient’s tumour, through the use
of defined CSC markers, may aid clinicians in defining more precise prognostic factors.
12. Resistance to therapy
Resistance to standard treatments, including radiation and chemotherapy regimens, fre‐
quently results in tumour relapse following a clinical response, due to the presence of resid‐
ual tumour cells. One of the key attributes of the CSC, which highlights their importance in
tumour development and maintenance, is the ability to resist chemotherapy-and radiation-
mediated treatment strategies. This has been observed in breast cancer patients, with the re‐
maining tumour cells following standard chemotherapy exhibiting both stem-and EMT-like
gene expression profiles [154]. The CSC-enriched component from breast cancer cell lines al‐
so display a decreased sensitivity to radiation [155]. In addition, following radiation treat‐
ment in glioblastoma, the recurring tumours tend to exhibit a distinct nodular pattern,
which is consistent with the theory of the recurring tumour arising from a clonal or sub-clo‐
nal source [156], likely due to the expansion of radio-resistant CSC. More recent studies
have identified a specific increase in the percentage of CSC within the radio-resistant tu‐
mours in glioblastoma and breast cancer both in patients and in culture [38, 155, 157]. Fur‐
thermore, the CSC population is specifically involved in the generation of new tumours
following treatment. This, coupled with the identification of both CSC and non-CSC cells
within the recurring tumour, is supportive of a specific subpopulation of cells, namely the
CSC, being responsible for the recurrent tumours.
The mechanism of therapy resistance in CSC is still largely unknown, however a number of
signalling pathways and molecules have been implicated in this process. Notably, resistance
is mediated by both extrinsic and intrinsic functions of the CSC, with extrinsically mediated
resistance governed by the CSC niche. The tumour environment, or niche, is well-document‐
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ed to mediate drug-resistance. This can be mediated both through the release of soluble fac‐
tors and via cell adhesion mechanisms, with the latter commonly referred to as cell
adhesion-mediated drug resistance (CAM-DR) (Reviewed by [158]). Both forms of niche-
mediated drug resistance are well established in haematological malignancies. The bone
marrow represents the most common site of metastases in these tumours and is character‐
ised as an environment rich in IL-6 and fibronectin, with both of these factors being demon‐
strated to contribute to the acquisition of drug resistance [159]. As described earlier, the
CXCL12-CXCR4 axis is an integral component in CSC homing to the niche and the colonisa‐
tion of the pre-metastatic niche. This axis has also been shown to be a key player in tumour
drug-resistance, with CXCR4 positive cells responding to stromal cell-derived CXCL12, re‐
sulting in increased activation of Akt/PKB and ERK signalling pathways which, in turn, me‐
diate resistance by inducing anti-apoptotic pathways [160-162]. Direct cellular interactions
mediated by adhesion between integrins and their receptors (often components of the ECM,
including collagen and fibronectin), have also been directly associated with a decrease in
drug-induced apoptosis [163, 164]. These studies show that CAM-DR is a key feature of che‐
motherapy resistance in tumours that is modulated by the niche. Due to the expression of
CXCR4 and a range of integrins by CSC, coupled with the key interactions observed be‐
tween CSC, the ECM and the CSC niche, it is likely that these mechanisms may be involved
in CSC-specific resistance pathways.
In addition, activation of signalling pathways and increased expression of key molecules
within the CSC themselves, provide an intrinsic means of modulating CSC resistance. The
Wnt and Notch pathways that are commonly involved in regulating stem cell growth and
behaviour have shown increased activation in response to irradiation and may confer radio-
resistance on the CSC population. Inhibiting the Notch pathway or specific knockdown of
Notch1 or Notch2 in glioma CSC sensitises these cells to radiation [165]. Furthermore, radia‐
tion-resistant CSC exhibit increased levels of stabilised β-catenin [157, 166], which suggests
abnormal activation of the Wnt signalling pathway. Further to these signalling pathways, a
population of stem-like cells identified in AML patients have been shown to exhibit a higher
degree of drug efflux than non-stem cells isolated from the tumour [167], suggesting a
mechanism by which the CSC component of tumours may be able to escape the effects of
chemotherapeutic agents. This phenomenon is likely due to the increased expression of
drug transporter genes ABCG2 and ABCA3 on CSC [168]. A further mechanism through
which CSCs have been demonstrated to exhibit radiation-resistance is through enhanced ac‐
tivation of DNA damage checkpoint responses. A study utilising glioblastoma-derived CSC,
prospectively isolated by their CD133+phenotype, showed that although DNA damage was
initiated equally in both CD133- and CD133+ cells following radiation, the CD133+ cells (rep‐
resenting the enriched CSC population) were better able to repair the damage and hence
displayed a lower rate of apoptosis [38]. It was subsequently shown that the DNA damage
checkpoint proteins CHK1 and CHK2 showed preferential activation in the CD133+ cells. In
addition, these cells also showed a basal level of activation of another component of the
DNA damage checkpoint, rad17. These data suggest that the CSC component of the tumour
is specifically primed to respond to DNA damage caused by external stress stimuli, such as
radiation, and as such exhibit increased survival following treatment. Furthermore, these
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studies suggest that radiation and chemotherapy resistance may be mediated by enhanced
Wnt and/or Notch signalling, enhanced DNA damage responses and differential expression
of drug transporter enzymes.
The observations detailed above explain why current cancer therapies are generally ineffec‐
tive – or at least why tumour recurrence is extremely common in aggressive tumour types.
Coupled with differential expression of key genes and pathways that can mediate cell sur‐
vival following radiation and chemotherapy, the CSC are generally slow cycling and are not
targeted by conventional therapies. In addition, CSC homing to the niche and subsequent
adhesion provides important support for the CSC and in turn mediates drug resistance.
Therefore, surviving CSC following treatment regimens continue to grow and differentiate
and are able to re-populate the tumour.
13. Targeting CSC and the CSC niche in cancer therapeutics
Tumour regression following treatment does not always correlate with patient survival, and
this is due largely to the remaining treatment-resistant CSC (as described above). Therefore,
directly targeting the CSC, in conjunction with existing therapeutics, may provide a novel
treatment strategy to eradicate the residual CSC and hence prevent tumour recurrence.
When investigating suitable target pathways, it is also important to factor in both the target‐
ing of the CSC population directly, as well as the CSC niche that supports their growth and
survival. As has been discussed throughout this chapter, the niche provides essential sup‐
port for CSC and disruption of these supportive processes presents an attractive focus for
the development of new therapies.
CSC rely on increased expression of the developmental signalling pathways – namely Wnt,
Notch and Hedgehog – to regulate their increased growth and survival. These pathways
therefore represent key targets for the development of novel treatment strategies that may
significantly inhibit the growth of the CSC population. Targeting the Notch pathway as a
means of specifically targeting the CSC component of tumours is reviewed in detail by Pan‐
nuti et al. [169]. Inhibition of the Notch signalling pathway has been demonstrated to be ef‐
fective in reducing the frequency of CSC derived from colon, medulloblastoma,
glioblastoma and breast cancer [115, 118, 119, 170]. Importantly, inhibition of Notch signal‐
ling prevented breast cancer metastases [170] and when used in combination with a com‐
mon chemotherapeutic agent delayed tumour recurrence [119]. As the Hedgehog pathway
represents an essential signalling component in CSC to modulate self-renewal and tumour-
initiating properties, targeting the Hedgehog pathway is another feasible therapeutic option
(reviewed by [171]). Proof-of-principle for Hedgehog as a therapeutic target is demonstrated
as inhibition of the hedgehog pathway results in a reduction in the tumourigenic capacity of
human gliomas in immune-compromised mice [101]. The resident CSC population is re‐
quired for the inherent tumourigenicty of glioma cells; therefore this data supports a role for
inhibition of hedgehog in directly affecting the CSC component of the tumour. Specific in‐
hibition of the hedgehog signalling pathway using cyclopamine is effective in preventing
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cancer growth as well as invasion and metastasis (another feature attributed to the CSC pop‐
ulation) [172, 173]. Cyclopamine has also been shown to specifically reduce the number of
CSC in pancreatic cancer [174], providing evidence that inhibition of the Hedgehog pathway
can directly affect the CSC population. In addition to targeting the Notch and Hedgehog sig‐
nalling pathways, as described here, inhibitors of Wnt signalling have also been developed
in recent years and have been shown to be effective in reducing tumour cell growth
[175-177]. Further development of these inhibitors and specific investigation of the effect of
treatment on the CSC population is warranted.
Further studies have demonstrated a possible role for targeting a range of small molecules
and proteins that play an integral role in the survival and growth of CSC. For example, the
CXCR1/CXCR2 inhibitor repertaxin functions to inhibit IL-8 responses, and as such depletes
the CSC component of breast cancer xenografts, resulting in a reduction in tumour growth
and metastases [142]. In addition, CXCR4 antagonists have been established and are under
investigation for clinical efficacy in treating leukaemia [91, 178]. Due to the high expression
of CXCR4 on CSC and the role of the CXCL12-CXCR4 axis in mediating metastasis and drug
resistance, these antagonists may also have a therapeutic role in targeting CSC and modulat‐
ing their ability to colonise the pre-metastatic niche. The use of CSC phenotypic markers as
possible additions to anti-tumour therapies is also beginning to be developed. A proof-of-
principle study has demonstrated that use of an anti-CD44 antibody was able to reduce the
number of tumour-initiating cells, both in vitro and in a xenograft model. In addition, this
reduction of CSC resulted in decreased growth, metastasis and post-radiation tumour recur‐
rence in mice [145]. In addition, targeting CD44 in AML has shown promise in eradicating
the CSC population and reducing the tumorigenic capacity of cells in vivo [179]. The resist‐
ance of CSC to conventional therapeutics is perhaps the most critical function of CSC that
must be overcome in the identification of novel therapeutic strategies. To this end, targeting
critical enzymes in the DNA damage response pathway, CHK1 and CHK2, has been shown
to reverse the radio-resistance observed in CD133 positive glioma CSC [38]. In addition,
pharmacological inhibition or targeted knockdown of ABC drug transporter enzymes may
provide useful tools to reverse chemoresistance of CSC [180, 181].
Perhaps as important as targeting the CSC specifically, is targeting the CSC niche. Disrup‐
tion of critical components of the CSC niche has the potential to inhibit CSC growth and
subsequently reduce tumour development and metastases. As tumour angiogenesis is sup‐
portive of CSC survival, anti-angiogenic treatments, when used in combination with cyto‐
toxic chemotherapies, can reduce the CSC population [182]. In particular, VEGF has been
shown to be expressed directly by CSC and by the tumour microenvironment and is an im‐
portant molecule in regulating vessel formation as well as CSC growth. Targeting VEGF
specifically with bevacizumab has been demonstrated to disrupt the CSC niche, and as such
result in a reduction in the number of CSC and subsequently tumour growth [79, 183]. Spe‐
cific disruption of cellular interactions between the CSC and stromal cells that comprise the
CSC-and pre-metastatic-niche may also contribute to the inhibition of CSC growth and
metastasis. For example, the fibronectin receptor VLA-4 is required for interactions between
tumour cells and stromal cells of the pre-metastatic niche and antibodies targeting this re‐
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ceptor are able to prevent this association and reduce tumour burden following treatment
[163, 184]. In addition, targeting this and similar interactions involving integrins in breast
cancer cells can restore cells to an epithelial-like state [185, 186] and therefore may be useful
in reversing the EMT which enhances the ability of malignant cells, specifically CSC, to met‐
astasise.
14. Concluding remarks
CSC display a dependence on their niche for growth and survival. Signalling through vari‐
ous developmental pathways and via a range of cytokines and growth factors not only mod‐
ulates CSC growth and function, but can also alter the composition of the CSC niche. The
ability of tumours to metastasise is a feature of CSC, due to their enhanced capacity for mi‐
gration and invasion. This process is reliant on the formation and regulation of a pre-meta‐
static niche, which is conducive to the colonisation of CSC and subsequent tumour growth
at a secondary site. Metastasis accounts for almost 90% of all cancer-associated deaths. A
better understanding of what drives tumour cells to metastasise and the changes in the host
tissue and local microenvironments that may accommodate the establishment and colonisa‐
tion of circulating tumour cells will increase our capacity to develop novel therapeutic
agents that may inhibit or delay metastasis and as such have a significant impact on patient
outcome. In addition, understanding the radio-and chemo-resistant properties of CSC has
allowed us to ascertain possible mechanisms for tumour recurrence and poor patient out‐
come following initial tumour regression.
Described in this chapter are but a few of the possible novel therapies that target CSC-specif‐
ic factors and/or components of the CSC niche. Further investigation of these, and others, as
well as the development of novel agents, is still required to better understand the feasibility
of direct targeting of CSC and/or their niche in cancer therapy. Furthermore, reliable bio‐
markers for the CSC population are required in order to accurately determine the efficacy of
these treatments. Importantly, the development of these novel therapeutics would not re‐
place existing effective treatment such as radiotherapy and cytotoxic chemotherapy, but
rather would be used in conjunction with these known and proven agents. Combination
therapies, such as these, as has already been demonstrated in a small number of in vivo stud‐
ies, would better enable us to effectively inhibit the CSC and the functionality of the CSC
niche, and subsequently lead to improved overall survival and reduced incidence of tumour
recurrence.
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